MMED.US MiniMed Group, Inc. Common Stock
- Market cap
- USD 5.06B
- P/E
- -
- P/B
- 1.40x
- ROE
- 0.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is MMED.US undervalued?
Graham numberThe Graham number of MiniMed Group, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MiniMed Group, Inc. Common Stock fundamental analysis
No fundamental analysis for MiniMed Group, Inc. Common Stock yet.
MiniMed Group, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MiniMed Group, Inc. Common Stock
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The c…
Full company profileMiniMed Group, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MiniMed Group, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.25B | 2.47B | 2.72B | 3.10B | 3.37B |
| Gross Profit | 1.31B | 1.44B | 1.53B | 1.68B | 1.86B |
| Operating Income | -69.0M | -69.0M | -202M | 49.0M | 152M |
| EBITDA | 39.0M | 59.0M | 107M | 205M | 316M |
| Net Income | -96.0M | -112M | -250M | -331M | 0.00 |
| EPS | -0.34 | -0.40 | -0.89 | -1.29 | 0.00 |
| Balance Sheet | |||||
| Total Assets | - | 4.09B | 4.20B | 4.63B | 4.72B |
| Total Liabilities | - | 646M | 870M | 1.02B | 1.10B |
| Shareholders' Equity | - | 3.45B | 3.33B | 3.61B | 3.62B |
| Cash & Short-term Investments | - | 54.0M | 11.0M | 298M | 207M |
| Total Debt | - | 8.00M | 11.0M | 145M | 59.0M |
| Cash Flow | |||||
| Operating Cash Flow | -6.00M | 41.0M | 140M | -197M | -196M |
| Capital Expenditure | 167M | 148M | 193M | 223M | 164M |
| Free Cash Flow | -173M | -107M | -53.0M | -420M | -360M |
| Ratios | |||||
| ROE | - | -3.2% | -7.5% | -9.2% | 0.0% |
| ROA | - | -2.7% | -6.0% | -7.1% | 0.0% |
| Net Profit Margin | -4.3% | -4.5% | -9.2% | -10.7% | 0.0% |
| Debt to Equity | - | 0.00x | 0.00x | 0.04x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MiniMed Group, Inc. Common Stock dividends
MiniMed Group, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns MiniMed Group, Inc. Common Stock
- Insiders 0.60%
- Institutions 26.54%
- Public & others 72.87%
- Shares outstanding 281M
- Free float 281M
Top funds holding MMED.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 7.31M | 2.60% | 0.00% | Oct 2026 |
| MFS Mid Cap Value A | 4.28M | 1.52% | -0.80% | Sep 2026 |
| iShares Russell 2000 Value ETF | 2.71M | 0.96% | 0.00% | Oct 2026 |
| Fidelity Select Medical Tech and Devcs | 2.54M | 0.90% | +37.43% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 1.49M | 0.53% | +0.24% | Oct 2026 |
| MFS New Discovery I | 867K | 0.31% | 0.00% | Sep 2026 |
| MFS New Discovery Value I | 847K | 0.30% | -4.64% | Sep 2026 |
| First Trust US Equity Opportunities ETF | 799K | 0.28% | 0.00% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 763K | 0.27% | 0.00% | Oct 2026 |
| MFS Mid Cap Growth A | 722K | 0.26% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 642K | 0.23% | +35.70% | Oct 2026 |
| T. Rowe Price New Horizons | 600K | 0.21% | +652.66% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 496K | 0.18% | +0.03% | Oct 2026 |
| JNL/MFS Mid Cap Value A | 490K | 0.17% | -0.49% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 467K | 0.17% | +713.14% | Oct 2026 |
| Fidelity Advisor Stock Selec Mid Cp I | 465K | 0.17% | 0.00% | Sep 2026 |
| UBS Lux Dgtl Hlth Eq Fd seeding P acc | 402K | 0.14% | 0.00% | Jul 2026 |
| Nuveen Quant Small Cap Equity R6 | 394K | 0.14% | +1.63% | Sep 2026 |
| abrdn Healthcare Investors | 361K | 0.13% | 0.00% | Oct 2026 |
| Putnam Global Health Care A | 346K | 0.12% | 0.00% | Sep 2026 |
Top institutions holding MMED.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Massachusetts Financial Services Company | 8.33M | 2.96% | +21.17% | Jun 2026 |
| Millennium Management LLC | 3.06M | 1.09% | +18.01% | Jun 2026 |
| Citadel Advisors Llc | 2.87M | 1.02% | +0.50% | Jun 2026 |
| Longaeva Partners L.P. | 2.81M | 1.00% | -11.50% | Jun 2026 |
| Sessa Capital, L.P | 2.00M | 0.71% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.00M | 0.71% | +7,527.47% | Jun 2026 |
| NORGES BANK | 1.96M | 0.70% | 0.00% | Jun 2026 |
| Rock Springs Capital Management LP | 1.52M | 0.54% | +44.08% | Jun 2026 |
| ExodusPoint Capital Management, LP | 1.44M | 0.51% | +251.15% | Jun 2026 |
| FMR Inc | 1.08M | 0.38% | -20.83% | Jun 2026 |
| Geode Capital Management, LLC | 956K | 0.34% | +288.74% | Jun 2026 |
| Boston Partners Global Investors, Inc | 902K | 0.32% | +6.79% | Jun 2026 |
| J. Goldman & Co LP | 830K | 0.30% | 0.00% | Jun 2026 |
| Nuveen, LLC | 539K | 0.19% | 0.00% | Jun 2026 |
| UBS Group AG | 413K | 0.15% | +32.78% | Jun 2026 |
| State Street Corp | 403K | 0.14% | 0.00% | Jun 2026 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 375K | 0.13% | -50.00% | Jun 2026 |
| First Trust Advisors L.P. | 366K | 0.13% | +269.41% | Jun 2026 |
| Vanguard Capital Management, LLC | 323K | 0.11% | 0.00% | Jun 2026 |
| Burkehill Global Management, LP | 300K | 0.11% | 0.00% | Jun 2026 |
MiniMed Group, Inc. Common Stock company profile
- Company name
- MiniMed Group, Inc. Common Stock
- Ticker
- MMED.US
- Exchange
- USA Stocks
- Listed since
- Mar 6, 2026
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 8,000
- Fiscal year end
- April
- Address
- 18000 Devonshire Street, Northridge, CA, United States, 91325
- Phone
- 763 514 4000
- Website
- minimed.com
About MiniMed Group, Inc. Common Stock
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.
MiniMed Group, Inc. Common Stock management
10- Ms. Que Thanh DallaraCEO & Director · born 1974
- Mr. Chad J. SpoonerExecutive VP & CFO · born 1972
- Mr. Ali DianatyExecutive VP and Chief Product & Technology Officer · born 1975
- Ms. Gillian ChandrasenaSenior VP & Chief Human Resources Officer · born 1974
- Mr. Christopher E. EsoPresident
- Mr. John GyurciVP, Chief Accounting Officer & Controller · born 1971
- Mr. Mike BruggemanSVP & Chief Information Officer
- Mr. Ryan WeispfenningHead of Investor Relations
- Ms. Sheila A. Denton J.D.Senior VP, General Counsel & Corporate Secretary · born 1966
- Ms. Kate Cronin MSN RNSVP and Chief Marketing & Communications Officer · born 1966